Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Common Equity (2023 - 2025)

Historic Common Equity for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $19.5 million.

  • BioLineRx's Common Equity rose 12966.49% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 12966.49%. This contributed to the annual value of $13.5 million for FY2024, which is 179.99% up from last year.
  • Per BioLineRx's latest filing, its Common Equity stood at $19.5 million for Q3 2025, which was up 12966.49% from $20.1 million recorded in Q2 2025.
  • BioLineRx's Common Equity's 5-year high stood at $39.1 million during Q1 2023, with a 5-year trough of $8.5 million in Q3 2024.
  • For the 3-year period, BioLineRx's Common Equity averaged around $17.8 million, with its median value being $14.0 million (2024).
  • As far as peak fluctuations go, BioLineRx's Common Equity plummeted by 6661.04% in 2024, and later soared by 12966.49% in 2025.
  • BioLineRx's Common Equity (Quarter) stood at $13.2 million in 2023, then rose by 1.8% to $13.5 million in 2024, then skyrocketed by 45.11% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $20.1 million for Q2 2025, and $20.9 million during Q1 2025.